1 / 29

Irritable Bowel Syndrome

Irritable Bowel Syndrome. John McLaughlin Clinical Lecturer/Consultant Gastroenterologist Hope Hospital, Salford. What is (are?) IBS? Symptoms and diagnosis Aetiology Therapy and management. IBS. What is IBS?. IBS is NOT a disease IBS is NOT a singular pathological entity

irish
Télécharger la présentation

Irritable Bowel Syndrome

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Irritable Bowel Syndrome John McLaughlin Clinical Lecturer/Consultant Gastroenterologist Hope Hospital, Salford.

  2. What is (are?) IBS? Symptoms and diagnosis Aetiology Therapy and management IBS

  3. What is IBS? • IBS is NOT a disease • IBS is NOT a singular pathological entity • IBS cannot have a single aetiology • but • IBS is a useful term, coined to group patients with similar, medically unexplained symptoms • IBS is difficult to manage, particularly pharmacologically

  4. IBS: features • IBS patients have symptoms characterised by • Unexplained abdominal pain • Disturbed bowel habit • Bloating • No ‘red flags’: bleeding, weight loss, abdominal masses, malnutrition etc • Clinical diagnosis here VERY SAFE <40-50 yrs • By definition, conventional investigations are normal: colonoscopy, histology, blood tests, radiology

  5. Current Diagnostic Criteria: Rome II 1999 • At least 12 weeks or more (in last year) of abdominal pain or discomfort with 2 out of 3 of the following: • Relieved by defaecation • Associated with change in stool frequency • >3/day or <3/week • Associated with change in stool form • Also supported by passage of mucus, bloating, straining, urgency, sense of incomplete evacuation

  6. PATIENT A Abdominal pain Urgent loose stool 3-4 times each morning Sense of incomplete evacuation PATIENT B Abdominal pain Strains to pass pellety stool every 3-4 days Bloating++ Problems with Rome II Can these very different patients really have the same disorder or common pathophysiology?

  7. ‘Diarrhoea-predominant’IBS • But when stools collected mean stool weight= 150g/day in ‘severe diarrhoea’ group • Diarrhoea is strictly >300g/day • More accurate to define as increased defaecatory frequency

  8. Are symptoms confined to the bowel in IBS patients? • NO! Seek and you shall find: • Functional Dyspepsia • Chronic Fatigue • Unexplained muscle pain (Fibromyalgia) • Temporomandibular dysfunction • Bladder symptoms • Gynaecological symptoms • Headaches • Backache • (All these body areas are normal too when investigated)

  9. IBS symptoms are common • 3-30% prevalence in unselected subjects • 5% of all visits to GPs • 25% of all visits to gastroenterologists • Estimated 1% annual incidence • No mortality from the disorder itself • cf mortality from drugs, investigations, surgical procedures

  10. IBS symptoms are common • 3-30% prevalence in unselected subjects • 5% of all visits to GPs • 25% of all visits to gastroenterologists • Estimated 1% annual incidence • No mortality from the disorder itself • cf mortality from drugs, investigations, procedures

  11. Alosetron: 5-HT3 antagonist (GSK) • Approved February 9, 2000, and voluntarily withdrawn from the market November 28, 2000.   -Women with diarrhoea-predominant IBS. • By November 10, 2000, FDA had reviewed 70 cases of serious post-marketing adverse events • 49 cases of ischaemic colitis • 21 cases of severe constipation. • Of the 70 cases, 34 resulted in hospitalization without surgery, 10 resulted in surgical procedures, and three resulted in death. • In some cases alosetron produced constipation serious enough to require surgery.  • ?1:350-700 risk of ischaemic colitis. • Put back on the market June 7, 2002 with stricter criteria, patient-doctor agreement

  12. Aetiology of FGID Aetiology of FGD ? Hypervigilance ? Hypervigilance ? Abnormal ( ? Abnormal ( processing processing ) ) ? Gut ? Gut Hypersensitivity Hypersensitivity Spinal Cord Spinal Cord Central Sensitisation ?motility disorder

  13. Altered Motility?- probably not • Evidence is inconsistent: maybe just epiphenomena of invasive study methods • Stress induces colonic contractility in IBS and control subjects • ‘Diarrhoea’-predominant • Prominent motility response to feeding • Some reports of accelerated transit and fast propagation of colonic contractions • Constipation-predominant • Some reports of reduced propagation of colonic contractions

  14. Where is the Problem ? Hypersensitive Gut ? ? ? Hypervigilant CNS?

  15. Functional gut disorders • ‘VISCERAL HYPERSENSITIVITY’ • Low thresholds to gut pain (eg inflating balloons in rectum, pain with lower volumes in ballon) • Perhaps reflects previous injury? • Inflammation, infection, nerve fibre injury (TAH) • akin to secondary hyperalgesia eg after burns • However, problem may still lie in central connections: why the associated disorders if due to gut injury??

  16. Post-infectious IBS • Post Campylobacter best reported (Spiller) • Persistent neuroimmune dysfunction • Persistent subtle inflammation • eg mast cell infiltration; increased permeability • Enteroendocrine cell hyperplasia • eg rectal 5-HT cells in rectum • Increased circulating 5-HT reported in females • ……‘IBS’ common in ‘IBD’

  17. Where is the Problem ? Hypersensitive Gut ? ? ? Hypervigilant CNS?

  18. Hypervigilance • Can alter sensory thresholds by focussing attention on any body area • If in pain, convinced something’s wrong, subject will focus attention there • Vicious circle of increasing symptoms could arise • Anxiety/depression heightens this further

  19. Prevalence of psychological problems • Community IBS: no excess • GP • Hospital • Cause of symptoms or driver to seek medical care? • Psychological factors may worsen outcome • eg physical or sexual abuse reportedly

  20. Adverse life events in the previous year: x 2 Female sex: x 3.4 Hypochondriasis: x 2 All 3 factors: x 7 Bacterial factors : 1 in 10 of Campylobacter infected individuals developed post-infective IBS compared with just 1 out of 100 with Salmonella Relative risk of postinfectious IBS- both biological and psychological!

  21. ‘Biopsychosocial model’ • Likely that components from each of these dimensions contribute to aetiology of IBS • …. and other functional gut disorders

  22. Therapeutic approach to IBS • Need a better understanding of precise causes in mechanistically defined patient subgroups, not just ROME compliant trials • Peripheral/central origins • Symptom-based approach: non-drug • Behavioural, psychological, hypnotherapy • Diet, exclusion • Symptom-based approach: drugs • NB 20-70% placebo responses • Placebo benefits last 12 months or more

  23. Therapeutic approach to IBS • Positive diagnosis, rather than just failure to find something else • Reassurance, minimal investigation • Explanation • ‘problem with the wiring rather than the plumbing’

  24. Evidence for Therapy in IBS • Fibre • Relieves constipation but worsens bloating • Loperamide: empirically helpful • Antispasmodics/anticholinergics • No good evidence • But may safely provide the placebo benefit

  25. Evidence for Therapy in IBS • Tricyclic antidepressants • Superior to placebo in meta-analysis • SSRIs • No definite benefit from trials • 5-HT3 antagonist (alosetron) • 12-17% benefit in female D-IBS • 5-HT4 agonist (tegasorod) • 5-15% benefit in female C-IBS • These need trials vs simple Rx not just placebo!

  26. Evolving Therapy in IBS • Novel agents in development • Antihypersensitivity • Peripheral opioid antagonists • Substance P, NMDA • Central pathways • Corticotrophin releasing hormone antagonists • Motility • CCK antagonists • Inflammation • Steroids unhelpful in PI-IBS • Probiotics….

  27. Summary and prospects • IBS will remain a major cause of morbidity until its constituent causes are better understood • As it has a social and experiential component, pharmacotherapy will largely be adjunctive at best • Naïve studies with agents affecting visceral sensitivity are the best hope at present

More Related